secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aura Biosciences, Inc. (AURA)
CIK:        0001501796
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001193125-25-278810
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aura Biosciences Q3 net loss $26.1M; Phase 3 CoMpass data expected Q4 2027
--------------------------------------------------------------------------

- Net loss of $26.1M in Q3 2025 vs $21.0M in Q3 2024; R&D expenses rose to $22.2M from $17.0M.
- Cash and marketable securities $161.9M; cash runway into first half 2027.
- Phase 3 CoMpass trial in early choroidal melanoma: enrollment completion expected 2026, topline data Q4 2027.
- Phase 1b/2 NMIBC trial on track for initial data mid-2026; immune profiling shows cold-to-hot tumor conversion.
- First patient dosed in Phase 2 choroidal metastases trial; entry criteria expanded to include all solid tumors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501796/000119312525278810/0001193125-25-278810-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501796/000119312525278810/aura-20251113.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-278810

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer